Alpha DNA Investment Management LLC Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Alpha DNA Investment Management LLC purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 7,818 shares of the company’s stock, valued at approximately $433,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $25,000. R Squared Ltd purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $53,000. FMR LLC boosted its position in shares of Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter worth $207,000. Finally, Summit Investment Advisors Inc. grew its stake in Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company’s stock worth $213,000 after buying an additional 244 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Insider Activity

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 2,137 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the sale, the insider now directly owns 46,355 shares of the company’s stock, valued at approximately $2,322,849.05. This trade represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Bryan Wahl sold 3,084 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $154,539.24. Following the transaction, the general counsel now directly owns 51,712 shares of the company’s stock, valued at approximately $2,591,288.32. The trade was a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock valued at $1,581,173 in the last three months. 8.25% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TARS shares. Barclays decreased their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Oppenheimer lifted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Guggenheim restated a “buy” rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Jefferies Financial Group lifted their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $63.67.

Tarsus Pharmaceuticals Stock Down 0.3 %

NASDAQ:TARS opened at $49.25 on Friday. The firm has a market capitalization of $1.89 billion, a P/E ratio of -12.93 and a beta of 0.94. The company’s fifty day moving average price is $47.76 and its 200-day moving average price is $47.69. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million. As a group, equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.